리서치사:Market Glass, Inc. (Formerly Global Industry Analysts, Inc.)
발행일:2024년 08월
페이지 정보:영문 250 Pages
라이선스 & 가격 (부가세 별도)
한글목차
신경교종 치료 세계 시장은 2030년까지 83억 달러에 달할 전망
2023년에 49억 달러로 추정되는 신경교종 치료 세계 시장은 분석 기간 2023-2030년에 CAGR 8.0%로 성장하고, 2030년에는 83억 달러에 이를 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 수술은 CAGR 6.8%로 성장을 지속하고, 분석 기간 종료 시 29억 달러에 달할 것으로 예측됩니다. 화학요법 분야의 성장률은 분석 기간 동안 CAGR 7.0%로 추정됩니다.
미국 시장은 13억 달러로 추정, 중국은 CAGR 7.7%로 성장 예측
미국의 신경교종 치료 시장은 2023년 13억 달러로 추정됩니다. 세계 2위 경제대국인 중국은 2030년까지 13억 달러 규모에 이를 것으로 예측되며, 분석 기간 2023-2030년의 CAGR은 7.7%입니다. 다른 주목할만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 7.1%와 6.9%로 예측되고 있습니다. 유럽에서는 독일이 CAGR 약 6.5%로 성장할 것으로 예측됩니다.
세계의 신경 교종 치료 시장 - 주요 동향과 촉진요인 요약
신경 교종은 중추 신경계의 뉴런을 지원하고 보호하는 신경 교세포에서 유래 한 다양한 뇌종양 그룹입니다. 신경 교종의 치료는 종양의 악성도, 부위 및 유전적 특성에 따라 크게 다릅니다. 교모세포종과 같은 악성도가 높은 신경교종은 특히 침공성이 높고 치료가 어려우므로 일반적으로 수술, 방사선 요법, 화학요법을 포함한 다제 병용 요법이 필요합니다. 경구 화학요법제인 테모졸로미드는 혈액뇌 장벽을 통과하는 능력이 있어 환자의 결과를 개선하기 때문에 방사선요법과의 병용이 일반적입니다. 분자 프로파일링의 최근 진보는 표적 요법과 면역요법이 특정 유전자 변이를 가진 환자에게 새로운 희망을 제공하는 등 보다 맞춤 치료 전략으로 이어지고 있습니다.
신경 교종의 혁신적인 치료는 생명 공학의 비약적 진보와 종양 생물학의 깊은 이해에 의해 추진되고 있습니다. 개인의 유전적 체질에 따라 치료를 조정하는 정밀의료 접근법은 효과를 높이고 부작용을 최소화하기 위해 채택되었습니다. 예를 들어, IDH1/2 억제제 및 EGFR 억제제와 같은 특정 돌연변이를 표적으로 하는 치료법은 임상시험에서 활발히 연구되고 있습니다. 또한, 체크포인트 억제제 및 CAR-T 세포 요법을 포함하는 면역요법은 신경교종 세포와 싸우기 위해 신체의 면역계를 이용하는 데 유망합니다. 대류 촉진 전달 및 나노입자 기반 캐리어와 같은 약물 전달 시스템의 발전으로 화학요법제의 표적 전달도 개선되고 있으며, 이로써 종양 부위의 농도를 증가시키면서 전신 독성을 완화할 수 있습니다.
신경 교종의 치료 시장의 성장은 여러 요인에 의해 견인되고 있습니다. 그 중에서도 중요한 것은 신경 교종의 발생률 증가와 효과적인 치료법에 대한 암멧 메디컬 요구의 높이입니다. 분자진단의 기술적 진보는 대처할 수 있는 유전자 변이의 확인을 가능하게 하고 표적 요법의 채용을 촉진합니다. 면역요법 분야의 확대와 다른 암종에서의 성공이 신경교종에 특이적인 면역 기반 치료에 대한 투자에 박차를 가하고 있습니다. 게다가, 새로운 약물 전달 메커니즘의 개발은 기존 치료의 정확성과 효능을 향상시키고 치료의 전망을 확대하고 있습니다. 뇌종양 연구에 대한 정부 및 민간 부문의 자금 지원은 희귀 질병 의약품 지정과 같은 규제적 우대 조치와 함께 시장 성장을 더욱 강화하고 있습니다. 또한, 신경교종의 증상에 대한 인식 증가와 영상 진단 기술의 진보는 조기 진단과 조기 개입에 기여하고, 치료 성적을 향상시키고, 선진 치료에 대한 수요를 촉진하고 있습니다. 이러한 요인들이 함께, 신경 교종 치료 시장은 역동적이고 빠르게 발전하고 있습니다.
조사 대상 기업 예(전 86건)
Amgen Inc.
Amneal Pharmaceuticals, LLC
Ariceum Therapeutics GmbH
Azurity Pharmaceuticals, Inc.(Gliade)
Bristol-Myers Squibb Company
CNS Therapeutics, Inc.
Denovo Biopharma LLC
Elekta
F. Hoffmann-La Roche Ltd.,
ITM Isotope Technologies Munich SE
Karyopharm Therapeutics, Inc.
Lantern Pharma Inc.
Novartis AG
Novocure
VBI Vaccines Inc.;
목차
제1장 조사 방법
제2장 주요 요약
시장 개요
주요 기업
시장 동향과 촉진요인
세계 시장 전망
제3장 시장 분석
미국
캐나다
일본
중국
유럽
프랑스
독일
이탈리아
영국
기타 유럽
아시아태평양
기타 지역
제4장 경쟁
JHS
영문 목차
영문목차
Global Glioma Treatment Market to Reach US$8.3 Billion by 2030
The global market for Glioma Treatment estimated at US$4.9 Billion in the year 2023, is expected to reach US$8.3 Billion by 2030, growing at a CAGR of 8.0% over the analysis period 2023-2030. Surgery, one of the segments analyzed in the report, is expected to record a 6.8% CAGR and reach US$2.9 Billion by the end of the analysis period. Growth in the Chemotherapy segment is estimated at 7.0% CAGR over the analysis period.
The U.S. Market is Estimated at US$1.3 Billion While China is Forecast to Grow at 7.7% CAGR
The Glioma Treatment market in the U.S. is estimated at US$1.3 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$1.3 Billion by the year 2030 trailing a CAGR of 7.7% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.1% and 6.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.5% CAGR.
Global Glioma Treatment Market - Key Trends and Drivers Summarized
Gliomas are a diverse group of brain tumors originating from glial cells, which support and protect neurons in the central nervous system. Treatment of gliomas varies significantly based on the tumor's grade, location, and genetic characteristics. High-grade gliomas, such as glioblastomas, are particularly aggressive and challenging to treat, necessitating a multimodal approach that typically includes surgery, radiation therapy, and chemotherapy. Temozolomide, an oral chemotherapy drug, is commonly used in combination with radiotherapy due to its ability to penetrate the blood-brain barrier and improve patient outcomes. Recent advancements in molecular profiling have led to more personalized treatment strategies, with targeted therapies and immunotherapies offering new hope for patients with specific genetic mutations.
Innovative treatments for glioma are being driven by breakthroughs in biotechnology and a deeper understanding of tumor biology. Precision medicine approaches, which tailor treatments based on an individual’s genetic makeup, are increasingly employed to enhance efficacy and minimize side effects. For instance, therapies targeting specific mutations such as IDH1/2 inhibitors and EGFR inhibitors are under active investigation in clinical trials. Additionally, immunotherapy, including checkpoint inhibitors and CAR-T cell therapy, has shown promise in harnessing the body’s immune system to combat glioma cells. Advances in drug delivery systems, such as convection-enhanced delivery and nanoparticle-based carriers, are also improving the targeted delivery of chemotherapeutic agents, thereby increasing their concentration at the tumor site while reducing systemic toxicity.
The growth in the glioma treatment market is driven by several factors. Key among these is the increasing incidence of gliomas and the significant unmet medical need for effective therapies. Technological advancements in molecular diagnostics have enabled the identification of actionable genetic mutations, driving the adoption of targeted therapies. The expanding field of immunotherapy and its success in other cancer types have spurred investment in glioma-specific immune-based treatments. Additionally, the development of novel drug delivery mechanisms has expanded the therapeutic landscape by improving the precision and efficacy of existing treatments. Government and private sector funding for brain cancer research, along with regulatory incentives such as orphan drug designations, further propel market growth. Moreover, growing awareness of glioma symptoms and advancements in imaging technologies contribute to earlier diagnosis and intervention, improving treatment outcomes and driving demand for advanced therapies. Collectively, these factors are fostering a dynamic and rapidly evolving market for glioma treatments.
Select Competitors (Total 86 Featured) -
Amgen Inc.
Amneal Pharmaceuticals, LLC
Ariceum Therapeutics GmbH
Azurity Pharmaceuticals, Inc. (Gliade)
Bristol-Myers Squibb Company
CNS Therapeutics, Inc.
Denovo Biopharma LLC
Elekta
F. Hoffmann-La Roche Ltd.,
ITM Isotope Technologies Munich SE
Karyopharm Therapeutics, Inc.
Lantern Pharma Inc.
Novartis AG
Novocure
VBI Vaccines Inc.;
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
Global Economic Update
Glioma Treatment - Global Key Competitors Percentage Market Share in 2024 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Rising Incidence of Gliomas Spurs Demand for Effective Therapies
Technological Advancements in Molecular Diagnostics Propel Growth
Precision Medicine Approaches Expand Addressable Market Opportunity
Development of Targeted Therapies Strengthens Business Case for Personalized Treatment
Increasing Adoption of Immunotherapy Drives Market Expansion
Novel Drug Delivery Systems Generate New Market Opportunities
Advances in Imaging Technologies Drive Early Diagnosis and Intervention
Growing Awareness of Glioma Symptoms Spurs Demand for Advanced Therapies
Here's How Molecular Profiling Enhances Treatment Personalization
Expanding Field of Genetic Research Generates Opportunities for Novel Treatments
Increasing Use of AI and Machine Learning in Drug Discovery Spurs Growth
Advances in Biomarker Identification Generate New Avenues for Targeted Therapy
Integration of Telemedicine and Remote Monitoring Technologies Expands Access to Care
Rising Investment in Oncology Propels Market Expansion for Glioma Treatments
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Glioma Treatment Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Glioma Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 3: World Historic Review for Glioma Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 4: World 16-Year Perspective for Glioma Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for Surgery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 6: World Historic Review for Surgery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 7: World 16-Year Perspective for Surgery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 9: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 10: World 16-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Radiation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 12: World Historic Review for Radiation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 13: World 16-Year Perspective for Radiation Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 15: World Historic Review for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 16: World 16-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 17: World Recent Past, Current & Future Analysis for Other Treatment Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 18: World Historic Review for Other Treatment Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 19: World 16-Year Perspective for Other Treatment Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
III. MARKET ANALYSIS
UNITED STATES
Glioma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
TABLE 20: USA Recent Past, Current & Future Analysis for Glioma Treatment by Treatment Type - Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 21: USA Historic Review for Glioma Treatment by Treatment Type - Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 22: USA 16-Year Perspective for Glioma Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types for the Years 2014, 2024 & 2030
CANADA
TABLE 23: Canada Recent Past, Current & Future Analysis for Glioma Treatment by Treatment Type - Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 24: Canada Historic Review for Glioma Treatment by Treatment Type - Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 25: Canada 16-Year Perspective for Glioma Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types for the Years 2014, 2024 & 2030
JAPAN
Glioma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
TABLE 26: Japan Recent Past, Current & Future Analysis for Glioma Treatment by Treatment Type - Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 27: Japan Historic Review for Glioma Treatment by Treatment Type - Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 28: Japan 16-Year Perspective for Glioma Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types for the Years 2014, 2024 & 2030
CHINA
Glioma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
TABLE 29: China Recent Past, Current & Future Analysis for Glioma Treatment by Treatment Type - Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 30: China Historic Review for Glioma Treatment by Treatment Type - Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 31: China 16-Year Perspective for Glioma Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types for the Years 2014, 2024 & 2030
EUROPE
Glioma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
TABLE 32: Europe Recent Past, Current & Future Analysis for Glioma Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 33: Europe Historic Review for Glioma Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 34: Europe 16-Year Perspective for Glioma Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
TABLE 35: Europe Recent Past, Current & Future Analysis for Glioma Treatment by Treatment Type - Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 36: Europe Historic Review for Glioma Treatment by Treatment Type - Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 37: Europe 16-Year Perspective for Glioma Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types for the Years 2014, 2024 & 2030
FRANCE
Glioma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
TABLE 38: France Recent Past, Current & Future Analysis for Glioma Treatment by Treatment Type - Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 39: France Historic Review for Glioma Treatment by Treatment Type - Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 40: France 16-Year Perspective for Glioma Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types for the Years 2014, 2024 & 2030
GERMANY
Glioma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
TABLE 41: Germany Recent Past, Current & Future Analysis for Glioma Treatment by Treatment Type - Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 42: Germany Historic Review for Glioma Treatment by Treatment Type - Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 43: Germany 16-Year Perspective for Glioma Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types for the Years 2014, 2024 & 2030
ITALY
TABLE 44: Italy Recent Past, Current & Future Analysis for Glioma Treatment by Treatment Type - Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 45: Italy Historic Review for Glioma Treatment by Treatment Type - Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 46: Italy 16-Year Perspective for Glioma Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types for the Years 2014, 2024 & 2030
UNITED KINGDOM
Glioma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
TABLE 47: UK Recent Past, Current & Future Analysis for Glioma Treatment by Treatment Type - Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 48: UK Historic Review for Glioma Treatment by Treatment Type - Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 49: UK 16-Year Perspective for Glioma Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types for the Years 2014, 2024 & 2030
REST OF EUROPE
TABLE 50: Rest of Europe Recent Past, Current & Future Analysis for Glioma Treatment by Treatment Type - Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 51: Rest of Europe Historic Review for Glioma Treatment by Treatment Type - Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 52: Rest of Europe 16-Year Perspective for Glioma Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types for the Years 2014, 2024 & 2030
ASIA-PACIFIC
Glioma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
TABLE 53: Asia-Pacific Recent Past, Current & Future Analysis for Glioma Treatment by Treatment Type - Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 54: Asia-Pacific Historic Review for Glioma Treatment by Treatment Type - Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 55: Asia-Pacific 16-Year Perspective for Glioma Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types for the Years 2014, 2024 & 2030
REST OF WORLD
TABLE 56: Rest of World Recent Past, Current & Future Analysis for Glioma Treatment by Treatment Type - Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 57: Rest of World Historic Review for Glioma Treatment by Treatment Type - Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 58: Rest of World 16-Year Perspective for Glioma Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types for the Years 2014, 2024 & 2030
